[1] K. Nakanishi, T. Yoshimoto, H. Tsutsui, H. Okamura, Interleukin-18 regulates both
Th1 and Th2 responses, Annu. Rev. Immunol. 19 (2001) 423–474, https://doi.org/
10.1146/annurev.immunol.19.1.423.
[2] G. Kaplanski, Interleukin-18: biological properties and role in disease pathogenesis,
Immunol. Rev. 281 (2018) 138–153, https://doi.org/10.1111/imr.12616.
[3] A. Mantovani, C.A. Dinarello, M. Molgora, C. Garlanda, Interleukin-1 and related
cytokines in the regulation of inflammation and immunity, Immunity 50 (2019)
778–795, https://doi.org/10.1016/j.immuni.2019.03.012.
[4] D.E. Place, T.D. Kanneganti, Recent advances in inflammasome biology, Curr.
Opin. Immunol. 50 (2018) 32–38, https://doi.org/10.1016/j.coi.2017.10.011.
[5] N. Van Opdenbosch, M. Lamkanfi, Caspases in cell death, inflammation, and
disease, Immunity 50 (2019) 1352–1364, https://doi.org/10.1016/j.
immuni.2019.05.020.
[6] P. Broz, P. Pelegrín, F. Shao, The gasdermins, a protein family executing cell death
and inflammation, Nat. Rev. Immunol. 20 (2020) 143–157, https://doi.org/
10.1038/s41577-019-0228-2.
[7] S. Banerjee, J.S. Bond, Prointerleukin-18 is activated by meprin beta in vitro and in
vivo in intestinal inflammation, J. Biol. Chem. 283 (2008) 31371–31377, https://
doi.org/10.1074/jbc.M802814200.
[8] R. Hanamsagar, V. Torres, T. Kielian, Inflammasome activation and IL-1β/IL-18
processing are influenced by distinct pathways in microglia, J. Neurochem. 119
(2011) 736–748, https://doi.org/10.1111/j.1471-4159.2011.07481.x.
[9] L. Bossaller, P.I. Chiang, C. Schmidt-Lauber, S. Ganesan, W.J. Kaiser, V.
A. Rathinam, E.S. Mocarski, D. Subramanian, D.R. Green, N. Silverman, K.
A. Fitzgerald, A. Marshak-Rothstein, E. Latz, Cutting edge: FAS (CD95) mediates
noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent
manner, J. Immunol. 189 (2012) 5508–5512, https://doi.org/10.4049/
jimmunol.1202121.
[10] E. Korhonen, N. Piippo, M. Hytti, J.M.T. Hyttinen, K. Kaarniranta, A. Kauppinen,
Only IL-1β release is inflammasome-dependent upon ultraviolet B irradiation
although IL-18 is also secreted, Faseb. J. 34 (2020) 6437–6448, https://doi.org/
10.1096/fj.201902355RR.
[11] N. Tsutsumi, T. Kimura, K. Arita, M. Ariyoshi, H. Ohnishi, T. Yamamoto, X. Zuo,
K. Maenaka, E.Y. Park, N. Kondo, M. Shirakawa, H. Tochio, Z. Kato, The structural
Y. Uchida et al.
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
Archives of Biochemistry and Biophysics 727 (2022) 109322
basis for receptor recognition of human interleukin-18, Nat. Commun. 5 (2014)
5340, https://doi.org/10.1038/ncomms6340.
H. Wei, D. Wang, Y. Qian, X. Liu, S. Fan, H.S. Yin, X. Wang, Structural basis for the
specific recognition of IL-18 by its alpha receptor, FEBS Lett. 588 (2014)
3838–3843, https://doi.org/10.1016/j.febslet.2014.09.019.
D. Novick, S.H. Kim, G. Fantuzzi, L.L. Reznikov, C.A. Dinarello, M. Rubinstein,
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response,
Immunity 10 (1999) 127–136, https://doi.org/10.1016/s1074-7613(00)80013-8.
Y. Aizawa, K. Akita, M. Taniai, K. Torigoe, T. Mori, Y. Nishida, S. Ushio, Y. Nukada,
T. Tanimoto, H. Ikegami, M. Ikeda, M. Kurimoto, Cloning and expression of
interleukin-18 binding protein, FEBS Lett. 445 (1999) 338–342, https://doi.org/
10.1016/s0014-5793(99)00148-9.
T. Takahashi, M.K. Ellingson, P. Wong, B. Israelow, C. Lucas, J. Klein, J. Silva,
T. Mao, J.E. Oh, M. Tokuyama, P. Lu, A. Venkataraman, A. Park, F. Liu, A. Meir,
J. Sun, E.Y. Wang, A. Casanovas-Massana, A.L. Wyllie, C.B.F. Vogels, R. Earnest,
S. Lapidus, I.M. Ott, A.J. Moore, A. Shaw, J.B. Fournier, C.D. Odio, S. Farhadian,
C. Dela Cruz, N.D. Grubaugh, W.L. Schulz, A.M. Ring, A.I. Ko, S.B. Omer,
A. Iwasaki, Sex differences in immune responses that underlie COVID-19 disease
outcomes, Nature 588 (2020) 315–320, https://doi.org/10.1038/s41586-0202700-3.
T.S. Rodrigues, K.S.G. de S´
a, A.Y. Ishimoto, A. Becerra, S. Oliveira, L. Almeida, A.
V. Gonçalves, D.B. Perucello, W.A. Andrade, R. Castro, F.P. Veras, J.E. TollerKawahisa, D.C. Nascimento, M.H.F. de Lima, C.M.S. Silva, D.B. Caetite, R.
B. Martins, I.A. Castro, M.C. Pontelli, F.C. de Barros, N.B. do Amaral, M.
C. Giannini, L.P. Bonjorno, M.I.F. Lopes, R.C. Santana, F.C. Vilar, M. AuxiliadoraMartins, R. Luppino-Assad, S.C.L. de Almeida, F.R. de Oliveira, S.S. Batah,
L. Siyuan, M.N. Benatti, T.M. Cunha, J.C. Alves-Filho, F.Q. Cunha, L.D. Cunha, F.
G. Frantz, T. Kohlsdorf, A.T. Fabro, E. Arruda, R.D.R. de Oliveira, P. LouzadaJunior, D.S. Zamboni, Inflammasomes are activated in response to SARS-CoV-2
infection and are associated with COVID-19 severity in patients, J. Exp. Med. 218
(2021), https://doi.org/10.1084/jem.20201707.
K. Yasuda, K. Nakanishi, H. Tsutsui, Interleukin-18 in health and disease, Int. J.
Mol. Sci. 20 (2019), https://doi.org/10.3390/ijms20030649.
R. Fusco, R. Siracusa, T. Genovese, S. Cuzzocrea, R. Di Paola, Focus on the role of
NLRP3 inflammasome in diseases, Int. J. Mol. Sci. 21 (2020), https://doi.org/
10.3390/ijms21124223.
Y. Nariai, H. Kamino, E. Obayashi, H. Kato, G. Sakashita, T. Sugiura, K. Migita,
T. Koga, A. Kawakami, K. Sakamoto, K. Kadomatsu, M. Nakakido, K. Tsumoto,
T. Urano, Generation and characterization of antagonistic anti-human interleukin
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
(IL)-18 monoclonal antibodies with high affinity: two types of monoclonal
antibodies against full-length IL-18 and the neoepitope of inflammatory caspasecleaved active IL-18, Arch. Biochem. Biophys. 663 (2019) 71–82, https://doi.org/
10.1016/j.abb.2019.01.001.
H. Yoshida, S.Y. Park, T. Oda, T. Akiyoshi, M. Sato, M. Shirouzu, K. Tsuda,
K. Kuwasako, S. Unzai, Y. Muto, T. Urano, E. Obayashi, A novel 3’ splice site
recognition by the two zinc fingers in the U2AF small subunit, Genes Dev. 29
(2015) 1649–1660, https://doi.org/10.1101/gad.267104.115.
K. Konishi, F. Tanabe, M. Taniguchi, H. Yamauchi, T. Tanimoto, M. Ikeda, K. Orita,
M. Kurimoto, A simple and sensitive bioassay for the detection of human
interleukin-18/interferon-gamma-inducing factor using human myelomonocytic
KG-1 cells, J. Immunol. Methods 209 (1997) 187–191, https://doi.org/10.1016/
S0022-1759(97)00164-6.
T.L. Born, E. Thomassen, T.A. Bird, J.E. Sims, Cloning of a novel receptor subunit,
AcPL, required for interleukin-18 signaling, J. Biol. Chem. 273 (1998)
29445–29450, https://doi.org/10.1074/jbc.273.45.29445.
R. Debets, J.C. Timans, T. Churakowa, S. Zurawski, R. de Waal Malefyt, K.
W. Moore, J.S. Abrams, A. O’Garra, J.F. Bazan, R.A. Kastelein, IL-18 receptors,
their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent
antagonist of IL-18, J. Immunol. 165 (2000) 4950–4956, https://doi.org/10.4049/
jimmunol.165.9.4950.
H. Cheung, N.J. Chen, Z. Cao, N. Ono, P.S. Ohashi, W.C. Yeh, Accessory proteinlike is essential for IL-18-mediated signaling, J. Immunol. 174 (2005) 5351–5357,
https://doi.org/10.4049/jimmunol.174.9.5351.
D.A.B. Rex, N. Agarwal, T.S.K. Prasad, R.K. Kandasamy, Y. Subbannayya, S.
M. Pinto, A comprehensive pathway map of IL-18-mediated signalling, J. Cell
Commun. Signal 14 (2020) 257–266, https://doi.org/10.1007/s12079-019-005444.
H. Kaplon, J.M. Reichert, Antibodies to watch in 2021, mAbs 13 (2021), 1860476,
https://doi.org/10.1080/19420862.2020.1860476.
A. Morell, W.D. Terry, T.A. Waldmann, Metabolic properties of IgG subclasses in
man, J. Clin. Invest. 49 (1970) 673–680, https://doi.org/10.1172/jci106279.
P. Vieira, K. Rajewsky, The half-lives of serum immunoglobulins in adult mice, Eur.
J. Immunol. 18 (1988) 313–316, https://doi.org/10.1002/eji.1830180221.
P.R. Hinton, M.G. Johlfs, J.M. Xiong, K. Hanestad, K.C. Ong, C. Bullock, S. Keller,
M.T. Tang, J.Y. Tso, M. V´
asquez, N. Tsurushita, Engineered human IgG antibodies
with longer serum half-lives in primates, J. Biol. Chem. 279 (2004) 6213–6216,
https://doi.org/10.1074/jbc.C300470200.
...
論文の公開元へ
